Prestige and Pharmapark make deal for trastuzumab biosimilar

Home/Pharma News | Posted 09/08/2019 post-comment0 Post your comment

Singapore-based Prestige BioPharma (Prestige) and Russia-based Pharmapark announced on 8 July 2019 that they had signed an exclusive partnership and supply agreement for Prestige’s candidate trastuzumab biosimilar (HD201) in Russia.


Trastuzumab is a monoclonal antibody that interferes with the human epidermal growth factor receptor 2 (HER2)/neu receptor. In some cancers, notably certain types of breast cancer, HER2 is overexpressed, and causes cancer cells to reproduce uncontrollably. Trastuzumab is therefore used to treat certain breast cancers.

According to the deal, Pharmapark will have exclusive rights to commercialize the trastuzumab biosimilar in Russia. Although the terms of the deal are not being disclosed, the companies say that Prestige will assume responsibility for product commercial supply out of its manufacturing facilities in Osong, Korea, while Pharmapark will be responsible for local registration, sales and marketing in Russia with the option to manufacture the product in Russia in line with the Russian import substitution strategy.

Prestige had the regulatory submission for its proposed trastuzumab biosimilar Tuznue (HD201) accepted by the European Medicines Agency in May 2019 [1]. Prestige also says that it intends to file its application for HD201 with the US Food and Drug Administration in 2019. Prestige also has a bevacizumab biosimilar (HD204) in phase III, an adalimumab biosimilar (PBP1502) in phase I and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in preclinical stages.

Related article
Positive phase III results for trastuzumab biosimilar HD201

1. GaBI Online - Generics and Biosimilars Initiative. Trastuzumab biosimilar from Prestige accepted for review by EMA []. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 9]. Available from: 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: Prestige

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010